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Sleep homeostasis depends on the length and quality (occurrence of stressful events, 
for instance) of the preceding waking time. Forced wakefulness (sleep deprivation or 
sleep restriction) is one of the main tools used for the understanding of mechanisms that 
play a role in homeostatic processes involved in sleep regulation and their interrelations. 
Interestingly, forced wakefulness for periods longer than 24 h activates stress response 
systems, whereas stressful events impact on sleep pattern. Hypothalamic peptides 
(corticotropin-releasing hormone, prolactin, and the CLIP/ACTH18–39) play an important 
role in the expression of stress-induced sleep effects, essentially by modulating rapid 
eye movement sleep, which has been claimed to affect the organism resilience to the 
deleterious effects of stress. Some of the mechanisms involved in the generation and 
regulation of sleep and the main peptides/hypothalamic hormones involved in these 
responses will be discussed in this review.
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inTRODUCTiOn
The purpose of the present review is not to present a detailed description of the neural basis of sleep 
generation and maintenance. For that, we refer to a number of previous review papers that cover 
this subject (1–5).
Sleep is a fundamental behavior for the individual’s survival and is redundantly regulated by the 
interaction of several neurotransmitter and neuropeptide systems acting on several brain struc-
tures, mainly located in the hypothalamus and brain stem [for review, see Ref. (6)]. In humans and 
rodents, sleep is classified into two main stages: non-rapid eye movement sleep (NREMS) and rapid 
eye movement sleep (REMS), which electroencephalographic features, in rats, are represented in 
Figure 1. In humans, NREMS encompasses three stages, N1, N2, and N3, characterized by synchro-
nized, high amplitude, and low frequency cortical waves, whereas in rats, NREMS or slow wave sleep 
can be distinguished into two substages, differing in the amplitude of these slow waves (low- and 
high-amplitude waves). REMS or paradoxical sleep (used for rats, since they show very little eye 
movements) is characterized by desynchronized, high frequency, low-amplitude cortical waves, very 
similar to wakefulness, and hippocampal theta waves. In addition, muscle atonia is a main tonic 
feature of this sleep stage (7, 8).
FigURe 1 | electro-oscillographic signs of wakefulness and sleep in the Wistar rat. (A) Active wake (with low voltage and fast EEG frequency, concomitant 
a high EMG activity and EKG is fast), (B) non-rapid eye movement sleep (NREMS—high amplitude and slow wave EEG, activity in EMG is low and EKG is low), (C) 
rapid eye movement sleep (REMS—theta 6–8 Hz activity is present in this medial EEG, EMG is almost quiet, and EKG shows an intermediate activity). EEG, 
electroencephalogram (obtained from a medial frontoparietal bipolar deviation); EMG, electromyogram (from the trapezius muscle); EKG, electrocardiogram (from 
intercostal electrodes). Signs were calibrated with 50-µV pulse. Data from our group.
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SLeeP RegULATiOn AnD HOMeOSTASiS
Circadian and Homeostatic Mechanisms
Sleep is regulated by a combination of homeostatic and circadian 
mechanisms. The homeostatic process refers to sleep needs 
or pressure, and the circadian one, entrainment to the light/
dark cycle. Besides the homeostatic factor, the circadian aspect 
is important and is related to the animal’s expression of daily 
preference for sleep/rest. Also, the duration of the sleep episodes 
appears to be greater in animals that are at the top of the food 
chain, since preys need to monitor the environment constantly 
to ensure their integrity, thus sleeping very short bouts (9, 10). 
The interaction between homeostatic (called “S process”) and 
circadian factors (called “C process”) in sleep regulation led some 
authors to propose a model in which the two processes would act 
together. Sleep begins wherever there is a conjunction of larger 
homeostatic pressure (need for sleep) and greater circadian 
predisposition (proximity to the phase of the cycle that sleep 
normally occurs), whereas it ends when this interaction decreases 
(11, 12).
Sleep homeostasis depends, among many factors, on the 
length and quality of the preceding waking period. Therefore, 
longer periods of waking lead to greater compensatory sleep, 
also known as rebound sleep. Interestingly, brief periods of sleep 
deprivation (SD) (3–6 h) result only in increased NREMS without 
affecting REMS (13). A total of 12–24 h of total sleep deprivation 
increases both NREMS and REMS (14–16), whereas total SD for 
96 h induces a very pronounced increase in REMS (17). In 1960, 
few years after the discovery of REMS, William Dement (18) 
reported, for the first time in humans, that selective REMS dep-
rivation induces a compensatory increase of this specific phase, 
e.g., REMS rebound. These effects have been replicated in rats, 
using the platform method that produces a complete suppression 
of REMS and some loss of NREMS (19, 20).
effects of Stress
It is interesting to note that REMS deprivation induces the acti-
vation of the hypothalamic–pituitary–adrenal (HPA) axis, with 
increased production (21, 22) and release (23) of corticotropin-
releasing hormone (CRH), and increased ACTH (24, 25) and 
corticosterone plasma levels (22, 26–28). This constellation of 
neuroendocrine changes indicates the stressful nature of this 
manipulation, thereby leading some authors to question whether 
sleep rebound would be an outcome of stress exposure. It soon 
became clear that stressful events can alter sleep pattern in a 
stimulus- and length-related fashion, inasmuch as immobiliza-
tion stress increases REMS (29), social conflict (30) and exposure 
to cold (31) induce NREMS, whereas unpredictable footshock 
stress decreases REM sleep (32, 33). One to two hours of immobi-
lization stress in the beginning of the dark phase, increase REMS, 
but longer periods of stress blunt the expression of sleep rebound 
(34), similar to what is seen with repeated immobilization (29). 
These opposite effects between acute and chronic exposure to the 
stress seem to be due to an adaptation phenomenon, which is 
also observed with footshock stress (32, 35). Either increased or 
reduced stress-induced REMS appear to be related to corticoster-
one secretion, in an inverted U shape fashion (36, 37).
HORMOnAL RegULATiOn OF STReSS-
inDUCeD SLeeP ReBOUnD
HPA Axis
Abnormal functioning of the HPA axis substantially changes 
the sleep pattern, as observed in Addison’s disease patients who 
exhibit adrenal insufficiency and display more NREMS and less 
REMS (34); this sleep abnormality can be corrected by corticoid 
replacement therapy (38). Conversely, patients with Cushing’s 
syndrome, who exhibit exaggerated cortisol secretion, display 
less NREMS and more awakenings during the night, which can 
also be corrected by interventions that decrease production of 
glucocorticoids (GCs) (39, 40). These findings strongly suggest 
that optimal GC concentrations are essential for normal sleep 
patterns in humans (41, 42). In rats, a similar phenomenon is 
also observed, with high levels of corticosterone being especially 
detrimental to NREMS (43).
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The 41-aminoacid peptide CRH, its mRNA, and receptors 
are increased in stress situations, such as electric footshock (44), 
immobilization (45), restriction of food (46), and sleep depriva-
tion (21, 23). CRH stimulates the release of other proopiomelo-
nocortin (POMC)-derived peptides, including β-endorphin and 
alpha-melanocyte-stimulating hormone (α-MSH) (47–49). It dif-
ferentially stimulates the activity of the prohormone convertases 
(PC1 and PC2, mainly), which cleave POMC in its bioactive 
peptides (50, 51).
CRH reduces REM and NREMS and increases awakenings 
when injected intravenously (52) or after i.c.v. administration 
(53), whereas CRH type 1 receptor (CRH-R1) antagonists pro-
mote sleep (54, 55). CRH effects on sleep homeostatic regulation 
are also evident, for its administration immediately after sleep 
deprivation increases REMS rebound (56). Conversely, α-helical-
CRH9−41, a CRH-R1 antagonist inhibits REMS rebound induced 
by immobilization (57). Recently, we have demonstrated that both 
i.c.v. CRH or α-helical-CRH9−41 administration during REMS 
deprivation impairs sleep homeostasis, thereby decreasing the 
length of REMS episodes in the theta band energy (6.0–9.0 Hz), 
and decreases the time of REM and NREMS in the recovery 
period (58).
Corticotropin-Like intermediate Peptide 
(CLiP or ACTH18–39)
CLIP is a POMC derivative, well known for inducing long 
REMS episodes (59, 60). ACTH cleavage to CLIP and α-MSH is 
mediated by prohormone convertase 2 (PC2) and is stimulated 
by serotonin, via 5-HT2C receptors (61–63). This process occurs 
in the melanocytes of the pituitary pars intermedia and in two 
other distinct locations in the brain: the arcuate nucleus—Arc 
(and peri-arcuate) in the basomedial hypothalamus and in a cell 
group of the nucleus of the solitary tract (NST) (64, 65). There are 
also CLIP-containing fibers, originating in the Arc and projecting 
to the lateral, paraventricular, basal and preoptic hypothalamic 
regions, dorsal and medial raphe nucleus (DRN and MRN, 
respectively), and septal area (66–70) (Figure 2).
Initial studies on the effects of stress-induced REMS rebound 
show that 1 h of immobilization stress increases REMS 3 h after 
the end of the stressor, a time point that corresponds to the 
increased content of phosphorylated CLIP in the Arc (71, 72). 
Conversely, micro-infusion of CLIP into the DRN increases 
REMS, similar to that observed after acute immobilization stress 
(73–75). It has been hypothesized that stress induces 5-HT 
release from the raphe nuclei, which projections to the Arc lead 
to CLIP processing from POMC. When the stress finishes, 5-HT 
is reuptaken, whereas CLIP synthesis and release from the Arc 
still go on. Interestingly, immunoreactive CLIP fibers are found 
in the DRN, which are postulated to trigger the dendritic release 
of serotonin (76) by a process of extracellular diffusion (67). The 
dendritic release of 5-HT within the DRN inhibits further 5-HT 
synthesis and release, via 5HT1A autoreceptors (77, 78), a process 
commonly observed during REMS (79, 80). Confirmation of 
this mechanism was obtained by electrical stimulation of the 
DRN leading to release of 5-HT and indol compounds in the 
Arc, followed, 3 h later, by increased REMS (81) (Figure 2). It is 
worth mentioning that REMS induced by CLIP, more precisely 
the amino-terminal fragment ACTH20–24 (Val-Lys-Tyr-Pro), is 
characterized by extremely long episodes, usually above 7 min. 
This effect on REMS is not obtained with ACTH (ACTH1–39) or 
other active fragments, such as ACTH18–24 (60).
Prolactin and Prolactin-Releasing Peptide
Prolactin (PRL) is a polypeptide hormone consisting of 199 amino 
acid residues (in rats and mice, by 197 amino acid residues), which 
is synthesized and secreted by the anterior pituitary lactotrophs, 
under tonic dopaminergic inhibitory control (82, 83); the main 
function of pituitary PRL is to stimulate lactation in mammals 
(84). In humans, PRL is secreted mostly in the second half of the 
night (85), with a very clear circadian rhythm (86).
This hormone exhibits anxiolytic effects (87), inhibits the 
development of stress-induced gastric ulcers (88), and mitigates 
hormonal and neuronal responses to various stressors (89, 90). 
PRL also has an important neurotrophic effect and is involved 
with neurogenesis in various brain structures and cell cultures 
(91–96), preventing stress-induced decrease in neurogenesis in 
an animal model of chronic stress (96). PRL is closely associated 
with physiological stress response (97–99), and immunoreactive 
neurons are found in the lateral hypothalamus, Arc, and sur-
rounding areas, thereby innervating other hypothalamic nuclei, 
amygdala, nucleus accumbens, olfactory cortex, septum, the 
reticular formation region, parabrachial region, locus coeruleus, 
periaqueductal gray, and DRN (100), and presenting practically 
the same distribution of POMC and its derivatives, as evidenced 
by double labeling studies (101). Interestingly, such structures are 
particularly involved in the regulation of sleep and stress response 
(Figure 2).
Numerous evidence indicates that PRL may be another media-
tor of stress-induced REMS rebound phenomenon. On the one 
hand, movement restriction (102) and ether vapor exposure (103) 
increase PRL plasma levels and time in REMS in rodents. On 
the other hand, PRL infusion in the dorsolateral hypothalamus 
or in the lateral ventricle increases REMS during the light phase 
(104, 105). Recently, we also showed that footshock stress applied 
concomitantly to REMS deprivation produces substantial REMS 
rebound, by virtue of very long REM episodes. Plasma PRL and 
hypothalamic serotonin (5-HT) were the likely mediators of the 
major increase in REMS episode length (37). Serotonin stimulates 
PRL release (106, 107) and PRL also increases serotonin synthesis 
(108–111) (Figure 2). In addition, both PRL micro-infusion into 
the DRN (112) and systemic administration of PRL increases 
REMS (113), whereas anti-PRL antibody suppresses REMS in 
rats (114), and this phase of sleep is naturally reduced in mice 
genetically deficient for PRL (115).
Prolactin-releasing peptide (PRL-RP) acts on a seven-trans-
membrane G protein-coupled receptor promoting PRL release 
in vitro and in vivo (116, 117). Central PRL-RP administration 
increases REMS in rats in parallel to PRL circulating levels (118, 
119). Intriguingly, high PRL-RP concentrations also increase 
NREMS and have no effect on REMS (118, 119). In a somewhat 
contradictory way, PRL-RP has the ability to reduce the oscillatory 
activity in sections of the reticular thalamic tissue (120), which 
plays a fundamental role in the generation of NREMS (121).
FigURe 2 | Schematic model of the possible modulation of stress-induced rapid eye movement sleep rebound by PRL, CLiP, and PRL-RP. LC,  
locus coeruleus; LDT, laterodorsal tegmental nucleus; PPT, pedunculopontine tegmental nucleus; LH, lateral hypothalamic area; POA, preoptic area; Arcuate, 
arcuate nucleus of hypothalamus; Intl., thalamic intralaminar nuclei; Ret., reticular thalamic nucleus. For more details, please refer to the main text.
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COnCLUDing ReMARKS
Several experimental stressors (1) (122, 123) and SD protocols 
(124, 125) promote serotonin release from the dorsal raphe (see 
Figure 2). Ascending serotonergic projections stimulate CLIP 
and PRL production and release by the Arc and lateral hypo-
thalamic area (LH), respectively (2), which depend on gene 
transcription and protein synthesis (hence, the rebound hap-
pens only a few hours after exposure to the stressful stimulus). 
Serotonin- and PRL-dependent self-stimulating neural circuits 
(and probably PrRP of the anterior preoptic area) (3), producing 
GABAergic inactivation of the DRN and LC on pontine nuclei 
(pedunculopontine tegmental/laterodorsal tegmental) (126). 
Furthermore, PRL can also activate the pontine cholinergic 
neurons directly (4) (127). Prolactinergic projections to DRN 
(5) (100, 101) induce serotonin release (112) that, at first, can 
feedback on the system leading to additional production and 
release of CLIP and PRL. However, 5-HT excess can stimulate 
self-receptors (5-HT1A) in the DRN, thereby inhibiting its 
activity (128, 129). All these phenomena contribute positively 
to REM sleep expression. Additionally, PrRP reduces the oscil-
latory activity of the reticular thalamic neurons (Ret.) (6) (120), 
an important structure for the generation of synchronized sleep 
(121), which also has positive effect on REM sleep. Without the 
inhibitory influence of the DRN and LC (130, 131), pontine 
cholinergic nuclei (7) stimulate the thalamic intralaminar 
nuclei (Intl.), which induces cortical activation during desyn-
chronized sleep and inhibits GABAergic neurons of thalamic 
reticular nucleus (132–134). We should emphasize that CLIP 
has inhibitory action (8) on serotonin release by the DRN 
(71), thereby contributing also to halt the suppressive activity 
that it has on pontine nuclei. It is noteworthy that there is a 
serotonergic ascending pathway, from the DRN to the septal 
area (9) that is responsible for the inhibitory activity in the 
cholinergic basal forebrain area, essential for hippocampal 
theta rhythm during REM sleep (135). This region also has a 
high density of PRL receptors (136) and can also be a potential 
site of prolactin action. Thus, PRL (10) also contributes to REM 
sleep expression.
REMS in mammals is involved with various functions, such 
as brain maturation of neonates (10), maintenance of minimal 
brain activity during sleep [which would allow a quick wake up 
and avoid a possible coma during sleep (137)], memory con-
solidation (138, 139), and maintenance of brain monoaminergic 
neurotransmitter systems (140–143), among others. Recently, 
however, studies have brought the attention to the importance 
of REMS in emotion regulation and the main adaptive function 
of REMS rebound after stress. This is well exemplified by studies 
showing that patients with posttraumatic stress disorder (PTSD) 
display longer latency to REMS, and short REM episodes and 
sleep fragmentation (144, 145). In a recent work, Mellman and 
colleagues assessed the sleep of individuals after a traumatic 
event and found a negative correlation between the duration 
of REMS episodes and development of PTSD. Furthermore, 
PTSD patients display reduced EEG high frequency activity 
during REMS, indicating low cognitive activation during this 
5Machado and Suchecki Regulation of Stress-Induced REM Sleep
Frontiers in Endocrinology | www.frontiersin.org December 2016 | Volume 7 | Article 163
sleep phase (146), thereby pointing to the need for long and 
consolidated REMS events to elaborate and integrate traumatic 
memories in conscious level (147). Therefore, we do not hesitate 
to propose, for reasons of evolutionary logic, that in rodents, 
increased REMS observed after some kinds of stress has a 
similar role (148).
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